Abstract
Summary
LPI (LP Information)' newest research report, the “Phosphoinositide 3-Kinase Inhibitor Industry Forecast” looks at past sales and reviews total world Phosphoinositide 3-Kinase Inhibitor sales in 2022, providing a comprehensive analysis by region and market sector of projected Phosphoinositide 3-Kinase Inhibitor sales for 2023 through 2029. With Phosphoinositide 3-Kinase Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Phosphoinositide 3-Kinase Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global Phosphoinositide 3-Kinase Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Phosphoinositide 3-Kinase Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Phosphoinositide 3-Kinase Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Phosphoinositide 3-Kinase Inhibitor and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Phosphoinositide 3-Kinase Inhibitor.
The global Phosphoinositide 3-Kinase Inhibitor market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Phosphoinositide 3-Kinase Inhibitor players cover Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc. and Secura Bio, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Phosphoinositide 3-Kinase Inhibitor market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Pan-PI3K Inhibitors
Dual PI3K/mTOR inhibitors
Other
Segmentation by application
CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma
FL - Follicular Iymphoma
Other Indications
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer AG
Gilead Sciences Inc.
Novartis AG
TG Therapeutics Inc.
Secura Bio, Inc.
This Insight Report provides a comprehensive analysis of the global Phosphoinositide 3-Kinase Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Phosphoinositide 3-Kinase Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Phosphoinositide 3-Kinase Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Phosphoinositide 3-Kinase Inhibitor and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Phosphoinositide 3-Kinase Inhibitor.
The global Phosphoinositide 3-Kinase Inhibitor market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Phosphoinositide 3-Kinase Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Phosphoinositide 3-Kinase Inhibitor players cover Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc. and Secura Bio, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Phosphoinositide 3-Kinase Inhibitor market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Pan-PI3K Inhibitors
Dual PI3K/mTOR inhibitors
Other
Segmentation by application
CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma
FL - Follicular Iymphoma
Other Indications
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer AG
Gilead Sciences Inc.
Novartis AG
TG Therapeutics Inc.
Secura Bio, Inc.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Phosphoinositide 3-Kinase Inhibitor Market Size 2018-2029
2.1.2 Phosphoinositide 3-Kinase Inhibitor Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Phosphoinositide 3-Kinase Inhibitor Segment by Type
2.2.1 Pan-PI3K Inhibitors
2.2.2 Dual PI3K/mTOR inhibitors
2.2.3 Other
2.3 Phosphoinositide 3-Kinase Inhibitor Market Size by Type
2.3.1 Phosphoinositide 3-Kinase Inhibitor Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Phosphoinositide 3-Kinase Inhibitor Market Size Market Share by Type (2018-2023)
2.4 Phosphoinositide 3-Kinase Inhibitor Segment by Application
2.4.1 CLL/SLL - Chronic Iymphocytic Ieukemia/Small Lymphocytic Lymphoma
2.4.2 FL - Follicular Iymphoma
2.4.3 Other Indications
2.5 Phosphoinositide 3-Kinase Inhibitor Market Size by Application
2.5.1 Phosphoinositide 3-Kinase Inhibitor Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Phosphoinositide 3-Kinase Inhibitor Market Size Market Share by Application (2018-2023)
3 Phosphoinositide 3-Kinase Inhibitor Market Size by Player
3.1 Phosphoinositide 3-Kinase Inhibitor Market Size Market Share by Players
3.1.1 Global Phosphoinositide 3-Kinase Inhibitor Revenue by Players (2018-2023)
3.1.2 Global Phosphoinositide 3-Kinase Inhibitor Revenue Market Share by Players (2018-2023)
3.2 Global Phosphoinositide 3-Kinase Inhibitor Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Phosphoinositide 3-Kinase Inhibitor by Regions
4.1 Phosphoinositide 3-Kinase Inhibitor Market Size by Regions (2018-2023)
4.2 Americas Phosphoinositide 3-Kinase Inhibitor Market Size Growth (2018-2023)
4.3 APAC Phosphoinositide 3-Kinase Inhibitor Market Size Growth (2018-2023)
4.4 Europe Phosphoinositide 3-Kinase Inhibitor Market Size Growth (2018-2023)
4.5 Middle East & Africa Phosphoinositide 3-Kinase Inhibitor Market Size Growth (2018-2023)
5 Americas
5.1 Americas Phosphoinositide 3-Kinase Inhibitor Market Size by Country (2018-2023)
5.2 Americas Phosphoinositide 3-Kinase Inhibitor Market Size by Type (2018-2023)
5.3 Americas Phosphoinositide 3-Kinase Inhibitor Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Phosphoinositide 3-Kinase Inhibitor Market Size by Region (2018-2023)
6.2 APAC Phosphoinositide 3-Kinase Inhibitor Market Size by Type (2018-2023)
6.3 APAC Phosphoinositide 3-Kinase Inhibitor Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Phosphoinositide 3-Kinase Inhibitor by Country (2018-2023)
7.2 Europe Phosphoinositide 3-Kinase Inhibitor Market Size by Type (2018-2023)
7.3 Europe Phosphoinositide 3-Kinase Inhibitor Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Phosphoinositide 3-Kinase Inhibitor by Region (2018-2023)
8.2 Middle East & Africa Phosphoinositide 3-Kinase Inhibitor Market Size by Type (2018-2023)
8.3 Middle East & Africa Phosphoinositide 3-Kinase Inhibitor Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.1 Global Phosphoinositide 3-Kinase Inhibitor Forecast by Regions (2024-2029)
10.1.1 Global Phosphoinositide 3-Kinase Inhibitor Forecast by Regions (2024-2029)
10.1.2 Americas Phosphoinositide 3-Kinase Inhibitor Forecast
10.1.3 APAC Phosphoinositide 3-Kinase Inhibitor Forecast
10.1.4 Europe Phosphoinositide 3-Kinase Inhibitor Forecast
10.1.5 Middle East & Africa Phosphoinositide 3-Kinase Inhibitor Forecast
10.2 Americas Phosphoinositide 3-Kinase Inhibitor Forecast by Country (2024-2029)
10.2.1 United States Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.2.2 Canada Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.2.3 Mexico Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.2.4 Brazil Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.3 APAC Phosphoinositide 3-Kinase Inhibitor Forecast by Region (2024-2029)
10.3.1 China Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.3.2 Japan Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.3.3 Korea Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.3.4 Southeast Asia Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.3.5 India Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.3.6 Australia Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.4 Europe Phosphoinositide 3-Kinase Inhibitor Forecast by Country (2024-2029)
10.4.1 Germany Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.4.2 France Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.4.3 UK Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.4.4 Italy Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.4.5 Russia Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.5 Middle East & Africa Phosphoinositide 3-Kinase Inhibitor Forecast by Region (2024-2029)
10.5.1 Egypt Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.5.2 South Africa Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.5.3 Israel Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.5.4 Turkey Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.5.5 GCC Countries Phosphoinositide 3-Kinase Inhibitor Market Forecast
10.6 Global Phosphoinositide 3-Kinase Inhibitor Forecast by Type (2024-2029)
10.7 Global Phosphoinositide 3-Kinase Inhibitor Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Bayer AG
11.1.1 Bayer AG Company Information
11.1.2 Bayer AG Phosphoinositide 3-Kinase Inhibitor Product Offered
11.1.3 Bayer AG Phosphoinositide 3-Kinase Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Bayer AG Main Business Overview
11.1.5 Bayer AG Latest Developments
11.2 Gilead Sciences Inc.
11.2.1 Gilead Sciences Inc. Company Information
11.2.2 Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Product Offered
11.2.3 Gilead Sciences Inc. Phosphoinositide 3-Kinase Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Gilead Sciences Inc. Main Business Overview
11.2.5 Gilead Sciences Inc. Latest Developments
11.3 Novartis AG
11.3.1 Novartis AG Company Information
11.3.2 Novartis AG Phosphoinositide 3-Kinase Inhibitor Product Offered
11.3.3 Novartis AG Phosphoinositide 3-Kinase Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Novartis AG Main Business Overview
11.3.5 Novartis AG Latest Developments
11.4 TG Therapeutics Inc.
11.4.1 TG Therapeutics Inc. Company Information
11.4.2 TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Product Offered
11.4.3 TG Therapeutics Inc. Phosphoinositide 3-Kinase Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 TG Therapeutics Inc. Main Business Overview
11.4.5 TG Therapeutics Inc. Latest Developments
11.5 Secura Bio, Inc.
11.5.1 Secura Bio, Inc. Company Information
11.5.2 Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Product Offered
11.5.3 Secura Bio, Inc. Phosphoinositide 3-Kinase Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Secura Bio, Inc. Main Business Overview
11.5.5 Secura Bio, Inc. Latest Developments
12 Research Findings and Conclusion